Clinical trial
Docetaxel in Breast Cancer
NCT00312208 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00312208 |
|---|---|
| Title | Docetaxel in Breast Cancer |
| Official title | A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Cancer International Research Group (CIRG) |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, doxorubicin, cyclophosphamide, Docetaxel |
| Enrollment | 3,299 |
| Start date | Nov 1, 2001 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2013 |
| First posted | Apr 7, 2006 |
| Last update posted | Dec 30, 2013 |
| Countries | Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Cyprus, Czechia and 25 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: